| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1008077796 |
| P356 | DOI | 10.1186/CC11932 |
| P932 | PMC publication ID | 4056079 |
| P698 | PubMed publication ID | 23327199 |
| P5875 | ResearchGate publication ID | 234159671 |
| P2093 | author name string | Lei Chen | |
| Juan Chen | |||
| Yuanyuan Chen | |||
| Gang Ma | |||
| Jianfeng Wu | |||
| Zhijie He | |||
| Baochun Gu | |||
| Aihua Lin | |||
| Guanrong Zhang | |||
| Lixin Zhou | |||
| Yinan Li | |||
| Bin Ou-Yang | |||
| Xiaoqin Wu | |||
| Jiyun Liu | |||
| Xiangdong Guan | |||
| Zijun Zou | |||
| Minying Chen | |||
| Xinhua Qiang | |||
| Qiuye Kou | |||
| P2860 | cites work | Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. | Q55059115 |
| Measurement of monocytic HLA-DR (mHLA-DR) expression in patients with severe sepsis and septic shock: assessment of immune organ failure | Q56990174 | ||
| Thymosin 1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo | Q58855386 | ||
| Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock | Q60547646 | ||
| From lab to bedside: emerging clinical applications of thymosin α1 | Q61160529 | ||
| Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones | Q70359944 | ||
| Monocyte deactivation in septic patients: restoration by IFN-gamma treatment | Q73400029 | ||
| EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units | Q76401271 | ||
| Changes in blood lymphocyte populations after multiple trauma: association with posttraumatic complications | Q77733742 | ||
| [Clinical study and long-term evaluation of immunomodulation therapy on trauma, severe sepsis and multiple organ dysfunction syndrome patients] | Q79339673 | ||
| Pathophysiology of sepsis | Q80210901 | ||
| [Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin] | Q80216938 | ||
| Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China | Q81164639 | ||
| Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study | Q84408608 | ||
| Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 | ||
| Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 | Q24644984 | ||
| Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care | Q27860820 | ||
| Intensive insulin therapy and pentastarch resuscitation in severe sepsis | Q28264234 | ||
| Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels | Q28301776 | ||
| Efficacy and safety of recombinant human activated protein C for severe sepsis | Q29547839 | ||
| The pathophysiology and treatment of sepsis | Q29619103 | ||
| A prospective, observational registry of patients with severe sepsis: the Canadian Sepsis Treatment and Response Registry | Q33382250 | ||
| Deaths: final data for 2006. | Q33507382 | ||
| The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis | Q33679447 | ||
| Allocation concealment in randomised trials: defending against deciphering | Q34116070 | ||
| Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony | Q34585151 | ||
| Purification and Biological Activity of Thymosin, a Hormone of the Thymus Gland | Q34714588 | ||
| Changes of monocyte human leukocyte antigen-DR expression as a reliable predictor of mortality in severe sepsis | Q35908140 | ||
| Survival analysis of 314 episodes of sepsis in medical intensive care unit in university hospital: impact of intensive care unit performance and antimicrobial therapy. | Q36147653 | ||
| A clinical trial to maintain glycemic control in youth with type 2 diabetes | Q36340078 | ||
| Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance | Q36818200 | ||
| Effect of thymosin alpha-1 on subpopulations of Th1, Th2, Th17, and regulatory T cells (Tregs) in vitro | Q37370761 | ||
| Thymosin alpha1: the regulator of regulators? | Q37763964 | ||
| Thymosin alpha 1: past clinical experience and future promise | Q37763975 | ||
| Immunotherapy for sepsis--a new approach against an ancient foe. | Q42802907 | ||
| Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction | Q43519747 | ||
| Early prognosis in severe sepsis via analyzing the monocyte immunophenotype | Q44746328 | ||
| Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling | Q44776004 | ||
| Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study. | Q45984304 | ||
| A new immunomodulatory therapy for severe sepsis: Ulinastatin Plus Thymosin {alpha} 1. | Q46122546 | ||
| Thymosin alpha1- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria | Q46493394 | ||
| Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. | Q50738804 | ||
| Pioglitazone for diabetes prevention in impaired glucose tolerance. | Q51161029 | ||
| Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. | Q51639404 | ||
| Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. | Q51723077 | ||
| Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. | Q52909875 | ||
| Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. | Q53753081 | ||
| Drotrecogin alfa (activated) in adults with septic shock. | Q55056165 | ||
| P433 | issue | 1 | |
| P921 | main subject | multicenter clinical trial | Q6934595 |
| sepsis | Q183134 | ||
| P304 | page(s) | R8 | |
| P577 | publication date | 2013-01-17 | |
| P1433 | published in | Critical Care | Q5186602 |
| P1476 | title | The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial | |
| P478 | volume | 17 |
| Q92119262 | Advances in severe community-acquired pneumonia |
| Q47310265 | Advances in the understanding and treatment of sepsis-induced immunosuppression. |
| Q38801190 | Association between mRNA expression of CD74 and IL10 and risk of ICU-acquired infections: a multicenter cohort study |
| Q92356332 | Chinese guidelines for the diagnosis and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adults (2018 Edition) |
| Q38177276 | Critical care medicine 2013: a review and prospect |
| Q28074598 | Current epidemiology of sepsis in mainland China |
| Q97419666 | Early Immunoparalysis Was Associated with Poor Prognosis in Elderly Patients with Sepsis: Secondary Analysis of the ETASS Study |
| Q41509426 | Evaluation of thymosin α 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis |
| Q42087444 | Expert consensus on the perioperative management of patients with sepsis |
| Q38534271 | Historical review of thymosin α 1 in infectious diseases |
| Q41932446 | Host-directed therapies for bacterial and viral infections. |
| Q90261730 | Immune therapy in sepsis: Are we ready to try again? |
| Q38217723 | Immunomodulatory adjuvant therapy in severe community-acquired pneumonia |
| Q33749999 | Immunotherapy - a potential new way forward in the treatment of sepsis |
| Q92069830 | Improvement of Sepsis Prognosis by Ulinastatin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q52579155 | Innate Immunity in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and Its Implications for Therapy. |
| Q27691996 | Is boosting the immune system in sepsis appropriate? |
| Q51568615 | Is this critically ill patient immunocompromised? |
| Q38763684 | Misdirected Sympathy |
| Q34177314 | Role of circulating lymphocytes in patients with sepsis |
| Q59136322 | Sepsis and Nosocomial Infection: Patient Characteristics, Mechanisms, and Modulation |
| Q59708886 | Sepsis and septic shock |
| Q38541110 | Sepsis-induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy |
| Q38453261 | Sepsis: a roadmap for future research |
| Q38764864 | Sepsis: frontiers in supportive care, organisation and research |
| Q26747196 | The Efficacy and Immunomodulatory Effects of Ulinastatin and Thymosin α1 for Sepsis: A Systematic Review and Meta-Analysis |
| Q36135093 | The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials |
| Q30234689 | The immunopathology of sepsis and potential therapeutic targets |
| Q34427050 | Therapeutic interventions in sepsis: current and anticipated pharmacological agents |
| Q92053517 | Therapeutic strategies for critically ill patients with COVID-19 |
| Q52653082 | Thymosin α1 treatment reduces hepatic inflammation and inhibits hepatocyte apoptosis in rats with acute liver failure. |
| Q35091080 | Year in review 2013: Critical Care--sepsis |
Search more.